| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/23/2003 | WO2003006072A1 A method of treatment and/or prophylaxis of ulcers |
| 01/23/2003 | WO2003006066A1 Mixed complexes for masking the taste of bitter active substances |
| 01/23/2003 | WO2003006064A1 Pharmaceutical formulation for the intramuscular administration of fulvestrant |
| 01/23/2003 | WO2003006063A2 Formulation comprising fulvestrant |
| 01/23/2003 | WO2003006057A1 Composition and method for the treatment of disease |
| 01/23/2003 | WO2003006046A1 Use of antimicrobial peptides as preservatives in ophthalmic preparations including solutions emulsions and suspensions |
| 01/23/2003 | WO2003006045A2 Cxcl10 treatment of secondary tissue degeneration |
| 01/23/2003 | WO2003006044A1 Methods and compositions for controlling protein assembly or aggregation |
| 01/23/2003 | WO2003006040A1 Method for isolating terpene trilactones (ginkgolides, bilobalide) from leaves and pharmaceutical powders of ginkgo biloba |
| 01/23/2003 | WO2003006037A1 Remedies |
| 01/23/2003 | WO2003006031A1 Calcium salts with cytotoxic activity |
| 01/23/2003 | WO2003006029A1 Method of inducing apoptosis in cancer cells |
| 01/23/2003 | WO2003006028A1 Novel immunosuppressants |
| 01/23/2003 | WO2003006027A1 Combination of drospirenone and an estrogen sulphamate for hrt |
| 01/23/2003 | WO2003006026A1 Combinations for the treatment of inflammatory disorders |
| 01/23/2003 | WO2003006025A1 Methods and materials for treating bone conditions |
| 01/23/2003 | WO2003006024A1 Medicine containing pyrimidine derivative |
| 01/23/2003 | WO2003006022A1 Tetrahydroquinoline derivatives and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| 01/23/2003 | WO2003006021A1 Alpha-hydroxyamide statine derivatives for the treatment of alzh eimer's disease |
| 01/23/2003 | WO2003006020A1 Pyridin-2-yl-methlyamine derivatives for treating opioid dependence |
| 01/23/2003 | WO2003006019A1 Medicinal composition for treatment of interstitial cystitis |
| 01/23/2003 | WO2003006018A1 A composition for the protection and regeneration of nerve cells containing berberine derivatives |
| 01/23/2003 | WO2003006017A2 Use of certain castanospermine esters in the treatment of influenza virus infections |
| 01/23/2003 | WO2003006016A2 Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury |
| 01/23/2003 | WO2003006014A1 Medicine comprising combination of five-membered heterocyclic compound and drug compensating for or enhancing its activity |
| 01/23/2003 | WO2003006013A1 Diaminediols for the treatment of alzheimer's disease |
| 01/23/2003 | WO2003006010A1 Aerosol formulations of δ8 tetrahydrocannabinol |
| 01/23/2003 | WO2003006009A1 Compositions for reducing or preventing cellulite in mammalian skin |
| 01/23/2003 | WO2003006008A1 A method for treatment and/or prophylaxis |
| 01/23/2003 | WO2003006007A1 Use of compounds as functional antagonists to the central cannabinoid receptors |
| 01/23/2003 | WO2003006006A1 Use of matrix metalloproteinase inhibitors to mitigate nerve damage |
| 01/23/2003 | WO2003006005A1 Composition comprising sulfacetamide and a sunscreen for the treatment of rosacea |
| 01/23/2003 | WO2003006004A2 Pharmaceutical compositions for oral use, containing, in combination, metformin and glicazide, a sulphonyl urea |
| 01/23/2003 | WO2003006003A1 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| 01/23/2003 | WO2003006002A1 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| 01/23/2003 | WO2003006001A1 ß-ADRENERGIC BLOCKADE REVERSAL OF CATABOLISM AFTER SEVERE BURN |
| 01/23/2003 | WO2003006000A1 Remedies for allergic eye diseases |
| 01/23/2003 | WO2003005999A2 Methods of treating cytokine mediated diseases |
| 01/23/2003 | WO2003005998A2 A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent of modulating cholinergic function |
| 01/23/2003 | WO2003005997A1 A composition for use in prophylaxis and/or treatment |
| 01/23/2003 | WO2003005996A1 Programmable controlled release injectable opioid formulation |
| 01/23/2003 | WO2003005995A1 Core formulation comprising pioglitazone hydrochloride and a biguanide |
| 01/23/2003 | WO2003005994A1 Core formulation comprising troglitazone and a biguanide |
| 01/23/2003 | WO2003005993A1 Core formulation comprising troglitazone and a biguanide |
| 01/23/2003 | WO2003005991A1 A core formulation |
| 01/23/2003 | WO2003005990A1 Biocompatible composite |
| 01/23/2003 | WO2003005989A2 Granulates containing liposoluble substances and a process for the preparation thereof |
| 01/23/2003 | WO2003005988A1 Cosmetic and dermatological preparations containing creatine for treating and actively preventing dry skin and other negative alterations of the physiological homeostasis of healthy skin |
| 01/23/2003 | WO2003005980A2 Cosmetic and dermatological preparations containing carnitine |
| 01/23/2003 | WO2003005971A2 Tetracycline compounds having target therapeutic activities |
| 01/23/2003 | WO2003005970A2 Carvedilol polymorph |
| 01/23/2003 | WO2003005968A2 Dual release levodopa ethyl ester and decarboxylase inhibitor with immediate release levodopa |
| 01/23/2003 | WO2003005967A2 Dual release levodopa ethyl ester and decarboxylase in controlled release core |
| 01/23/2003 | WO2003005962A2 Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate |
| 01/23/2003 | WO2003005960A2 Novel bicyclic and tricyclic cannabinoids |
| 01/23/2003 | WO2003005956A2 A hydroxamic acid thrombospondin peptide analog that inhibits aggrecanase activity |
| 01/23/2003 | WO2003005955A2 Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
| 01/23/2003 | WO2003005954A2 Methods and materials for the treatment of testosterone deficiency in men |
| 01/23/2003 | WO2003005951A2 Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery |
| 01/23/2003 | WO2003005944A1 Sequential drug delivery systems |
| 01/23/2003 | WO2003005838A1 Food composition offering stress relaxation to mammals |
| 01/23/2003 | WO2003005837A1 Enteral formulations |
| 01/23/2003 | WO2003005822A1 Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants |
| 01/23/2003 | WO2002098367A3 Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering cns activity |
| 01/23/2003 | WO2002089945A3 Processes and apparatus for extraction of active substances and enriched extracts from natural products |
| 01/23/2003 | WO2002088143A3 Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands |
| 01/23/2003 | WO2002080842A3 Medicament and method for diagnosing an autoimmune condition_in particular psoriasis |
| 01/23/2003 | WO2002076475A3 Glycosaminoglycan anticoagulants derived from fish |
| 01/23/2003 | WO2002072114A3 Extracts of magnoliaceae plants and their use as anxiolytic and sedative agent |
| 01/23/2003 | WO2002072094A3 Use of neuroactive substances and combinations thereof for the treatment of parkinsons disease |
| 01/23/2003 | WO2002066475A3 Tricyclic androgen receptor modulator compounds |
| 01/23/2003 | WO2002060436A3 Use of fredericamycin a and its derivatives in the treatment of pin1-associated states |
| 01/23/2003 | WO2002056790A3 Delivery of therapeutic capable agents |
| 01/23/2003 | WO2002055055A3 Fast-acting antimicrobial lotion with enhanced efficacy |
| 01/23/2003 | WO2002055017A3 Method of treating autoimmune diseases |
| 01/23/2003 | WO2002053711A3 Use of transcription factor yb-1 in adenoviral systems |
| 01/23/2003 | WO2002053535A3 Process for making amlodipine, derivatives thereof, and precursors therefor |
| 01/23/2003 | WO2002053101A3 Method for treating fibrotic diseases or other indications |
| 01/23/2003 | WO2002051851A3 Pharmaceutical uses and synthesis of benzobicyclooctanes |
| 01/23/2003 | WO2002051808A3 Muscarinic antagonists |
| 01/23/2003 | WO2002050066A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/23/2003 | WO2002049617A3 Self forming, thermodynamically stable liposomes and their applications |
| 01/23/2003 | WO2002049413A3 Thrombopoietin mimetics |
| 01/23/2003 | WO2002047731A3 Drug delivery compositions and coated medical devices |
| 01/23/2003 | WO2002047456A3 Urotensin-ii receptor antagonists |
| 01/23/2003 | WO2002046364A9 Genes associated with mechanical stress, expression products therefrom, and uses thereof |
| 01/23/2003 | WO2002046171A3 Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto |
| 01/23/2003 | WO2002046138A3 Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines |
| 01/23/2003 | WO2002043662A3 Dietary composition containing conjugated linoleic acid and calcium for improved health |
| 01/23/2003 | WO2002041835A3 Estrogen receptor modulators |
| 01/23/2003 | WO2002038133A3 Compositions containing hydrolytically unstable compounds |
| 01/23/2003 | WO2002036767A3 Therapeutic oligonucleotides of reduced toxicity |
| 01/23/2003 | WO2002036562A3 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
| 01/23/2003 | WO2002036127A3 Methods and compositions for the treatment of polycystic ovary syndrome with chromium complexes |
| 01/23/2003 | WO2002033095A3 Regulation of human serine-threonine protein kinase |
| 01/23/2003 | WO2002024906A9 Induction of exon skipping in eukaryotic cells |
| 01/23/2003 | WO2002022559A3 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 01/23/2003 | WO2002020773A3 Chimeric antisense oligonucleotides of arabinofuranose analogues and deoxyribose nucleotides |
| 01/23/2003 | WO2002019998A3 A method of treating weight gain associated with atypical antipsychotic use |
| 01/23/2003 | WO2002019981A3 Cosmetic and pharmaceutical composition comprising chelating/sequestering agents and their cosmetic and dermatological use |